Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 4983-4988

  Wang, Ning Ning ^a   Zhao, Li Jun ^a   Wu, Li Nan ^a   He, Ming Feng ^b   Qu, Jun Wei ^a   Zhao, Yi Bing ^a   Zhao, Wan Zhou ^c   Li, Jie Shou ^d   Wang, Jin Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

^c Sino EU Biomedical Innovation Center (SEBIC)   (China)

^d NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

Multidrug resistance; Ovarian carcinoma; Signaling pathway; Taxol

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CAVEOLIN 1; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; PACLITAXEL; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; TUMOR PROTEIN;

ANIMAL; APOPTOSIS; CARCINOMA; CELL CYCLE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; NUDE MOUSE; OVARY TUMOR; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA; CAVEOLIN 1; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887594034     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.4983     Document Type: Article

References (27)

1. Cantley LC (2002). The phosphoinositide 3-kinase pathway. Science, 296, 1655-7.
2. Chauhan D, Tian Z, Nicholson B, et al (2012). A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell, 22, 345-58.
3. Di Michele M, Della Corte A, Cicchillitti L, et al (2009). A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim Biophys Acta, 1794, 225-36.
4. Doddareddy MR, Rawling T, Ammit AJ(2012).Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators.Curr Med Chem, 19, 163-73.
5. Downward J (2003). Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer, 3, 11-22.
6. Hiss D (2012). Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol, 2012, 737981.
7. Hoshino R, Chatani Y, Yamori T, et al (1999). Constitutive activation of the 41/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene, 18, 813-22.
8. Kim H, Park GS, Lee JE, et al (2013). A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells. Br J Cancer, 109, 351-9.
9. LeBlanc R, Catley LP, Hideshima T, et al(2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res, 62, 4996-5000.
10. Liu HZ, Yu C, Yang Z, et al (2011). Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways. Mol Med Report, 4, 985-92.
11. Mackay HJ, Twelves CJ (2003). Protein kinase C: a target for anticancer drugs? Endocr Relat Cancer, 10, 389-96.
12. McCubrey JA, Steelman LS, Chappell WH, et al (2012). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget, 3, 1068-111.
13. Navolanic PM, Steelman LS, McCubrey JA (2003). EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol, 22, 237-52.
14. Paraiso KH, Smalley KS (2013).Fibroblast-mediated drug resistance in cancer. Biochem Pharmacol, 85, 1033-41.
15. Pérez-Tomás R(2006). Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem, 13, 1859-76.
16. Salem AF, Bonuccelli G, Bevilacqua G, et al (2011). Caveolin-1 promotes pancreatic cancer cell differentiation and restores membranous E-cadherin via suppression of the epithelial-mesenchymal transition. Cell Cycle, 10, 3692-700.
17. Sui H, Fan ZZ, Li Q (2012).Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res, 40, 426-35.
18. Szakács G, Paterson J, Ludwig JA, et al (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 5, 219-34.
19. Tanaka Y, Gavrielides MV, Mitsuuchi Y, et al (2003). Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem, 278, 33753-62.
20. Wang JH, Zhao WZ, Chen XX, et al (2010). Establishment and biological characterization of Cisplatin-resistant cell line OV1228/Taxol of ovarian carcinoma. Chin J Cancer Prev Treat, 22, 281-4.
21. Wee S, Wiederschain D, Maira SM, et al (2008). PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A, 105, 13057-62.
22. Wen J, Zheng B, Hu Y, et al (2009). Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line. Oncol Rep, 22, 65-71.
23. Wu DL, Huang F, Lu HZ(2003). Drug-resistant proteins in breast cancer: recent progress in multidrug resistance [J]. Chin J Cancer, 22, 441-4. [in Chinese]
24. Yan XD, Li M, Yuan Y, et al (2007). Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol Rep, 17, 1163-9.
25. Yang SH, Sharrocks AD, Whitmarsh AJ (2013). MAP kinase signalling cascades and transcriptional regulation. Gene, 513, 1-13.
26. Zhao LJ, Xu H, Qu JW (2012). Modulation of drug resistance in ovarian cancer cells by inhibition of protein kinase C-alpha (PKC-α) with small interference RNA (siRNA) agents. Asian Pac J Cancer Prev, 13, 3631-6.
27. Zhe C, Li-Juan W, Ming Hui W, et al (2011). Mechanism governing reversal of multidrug resistance in human breast carcinoma cells by chelerythrine. Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 33, 45-50.